Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia

Fetal Diagnosis and Therapy

Volumn 33, Issue 3, 2013, Pages 149-155

  Lai, Jonathan ^a,b   Syngelaki, Argyro ^a   Poon, Leona C Y ^a   Nucci, Marta ^a,b   Nicolaides, Kypros H ^a,b,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c MEDWAY MARITIME HOSPITAL   (United Kingdom)

Author keywords

Preeclampsia; Pyramid of antenatal care; Soluble endoglin; Third trimester screening

Indexed keywords

ENDOGLIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; HUMAN; MATERNAL SERUM; MATERNAL SERUM SCREENING TEST; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY;

EID: 84876544201     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000343220     Document Type: Article

References (26)

1. World Health Organization (WHO): Make Every Mother and Child Count. WHO, 2005. Geneva, WHO, 2005.
2. Confidential Enquiry into Maternal and Child Health (CEMACH) Perinatal Mortality 2006: England, Wales and Northern Ireland. London, CEMACH, 2008.
3. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
4. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
5. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.
6. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol 2010; 116: 402-414.
7. Roberge S, Villa P, Nicolaides KH, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E: Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: A systematic review and meta-analysis. Fetal Diagn Ther 2012; 31: 141-146.
8. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
9. Stepan H, Kramer T, Faber R: Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007; 92: 2831-2834.
10. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y: Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007; 92: 2672-2679.
11. Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A: Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29: 555-563.
12. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R: Endoglin, PlGF and sflt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-842.
13. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT: The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009; 29: 464-470.
14. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S: Maternal circulating levels of activin a, inhibin a, sflt-1 and endoglin at parturition in normal pregnancy and preeclampsia. PLoS One 2009; 4:e4453.
15. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R: Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142.
16. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS: The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287.
17. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV: First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266,e1-e6.
18. Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, Chung JH, Lee SW, Ryu HM: Soluble endoglin and transforming growth factor-1 in women who subsequently developed preeclampsia. Prenat Diagn 2009; 29: 471-476.
19. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH: Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol 2010; 35: 680-687.
20. Gu Y, Lewis DF, Wang Y: Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260-266.
21. Robinson HP, Fleming JE: A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
22. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
23. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV.
24. Lai J, Poon LCY, Pinas A, Bakalis S, Nicolaides KH: Uterine artery Doppler at 30-33 weeks' gestation in the prediction of preeclampsia. Fetal Diagn Ther 2012, E-pub ahead of print.
25. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA: A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
26. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH: Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2012, E-pub ahead of print.